News

    Aptahem strengthens its research and development organisation with industrial expertise in cardiovascular diseases and clinical development

    2017-02-07

    Aptahem can today announce that it has entered into an agreement with lecturer and registered practitioner Anders Bylock, a well-known expert on issues related to cardiovascular treatment including pre-clinical development, clinical trials and regulatory submissions. Dr Bylock will provide...

    Read More

    Drug News publish updates from Aptahem

    2017-01-25

    QuintilesIMS publish updates from Aptahem in their newsletter Drug News in December 2016 (see page 15). Aptahem’s CEO Mikael Lindstam presented the information at Bio Europe in Cologne in November 2016. Open Drug News For further information: Mikael Lindstam,...

    Read More

    Article about aptamers published in a scientific journal

    2016-12-09

    In November 2016 Smith & Franklin published an article about aptamer. Read the article. For further information: Mikael Lindstam, CEO Aptahem AB Tel: + 46 (0)766-33 36 99 E-mail: ml@aptahem.com About Aptahem Aptahem is developing drug candidates for the...

    Read More

    Preclinical studies suggest great potential for Aptahems drug candidate Apta-1

    2016-10-07

    Aptahem, together with its US partner Hooke Laboratories in Boston, conducted preclinical studies on the anti-inflammatory effects of the drug candidate Apta-1 compared with Dexamethasone, one of the worldwide most prescribed drugs for inflammatory diseases. The studies indicate a...

    Read More

    New studies show APTA-1 has positive affect on key factors related to blood coagulation

    2016-08-31

    Aptahem announce that the results from studies carried out over recent months’, in a series of targeted animal studies, show that its lead compound APTA-1 demonstrates a positive effect on a number of key features related to the coagulation...

    Read More

    Aptahem starts close collaboration with leading research groups at the Nencki Institute in Warsaw

    2016-05-18

    Aptahem today announced that an extensive collaboration has begun with the Nencki Institute of Experimental Biology. Aptahem and various expert groups within the Institute will jointly examine the effects of the company’s developmental drug candidate, APTA-1. The Nencki Institute...

    Read More

    Aptahem enter cooperation agreement with leading research institute in hematology

    2016-04-24

    Aptahem announce they have entered a cooperation agreement with the Institute of Hematology and Blood Transfusion in Warsaw (IHIT), to identify APTA-1’s inhibitory mechanisms in the coagulation system. IHIT is Poland’s most prestigious hematology research institute and reference hospital....

    Read More